Sign in Subscribe

crc-research

A collection of 723 issues

DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC

Skip to content The CRC Digest DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC Preclinical study investigated why dMMR/MSI colorectal cancers are intrinsically immunogenic and why some do not respond or develop resistance to immune checkpoint inhibitors. (Gastroenterology) This content is informational only and does not

CRC Research Finding

Skip to content The CRC Digest ◇ Review examines anti-VEGF plus checkpoint inhibitor combinations in GI cancers A narrative review synthesizes preclinical and clinical data on combining anti-VEGF agents with immune checkpoint inhibitors across gastrointestinal cancers, including colorectal cancer, with emphasis on optimal sequencing strategies. (Discov Oncol) This content is informational

CRC Research Update — July 16, 2026

Today's colorectal cancer research highlights

Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination

Skip to content The CRC Digest Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84

RAS mutation linked to early progression in liver metastases conversion therapy

Skip to content The CRC Digest RAS mutation linked to early progression in liver metastases conversion therapy Retrospective study of 194 patients with initially unresectable, pMMR colorectal liver metastases found that RAS mutation status was associated with early progression or recurrence after conversion therapy. (Front Surg) This content is informational

Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC

Skip to content The CRC Digest Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol) This content is informational only and does not

New tool prioritizes colonoscopy for highest-risk patients

Skip to content The CRC Digest New tool prioritizes colonoscopy for highest-risk patients Decision-tree model using fecal hemoglobin and clinical data helps stratify CRC risk among those with positive fecal immunochemical tests, addressing colonoscopy capacity constraints. (Dig Endosc) This content is informational only and does not constitute medical advice. Always

Missed screening opportunities lead to emergency diagnosis and worse outcomes

Skip to content The CRC Digest Missed screening opportunities lead to emergency diagnosis and worse outcomes SEER-Medicare analysis of older adults found that many CRC cases are diagnosed during emergency presentation, which are linked to worse outcomes compared to screening-detected cases. (J Surg Oncol) This content is informational only and

Treatment variation impacts survival in early-onset metastatic CRC

Skip to content The CRC Digest Treatment variation impacts survival in early-onset metastatic CRC A retrospective analysis of patients diagnosed with stage IV CRC between 2004-2022 found that treatment patterns and outcomes varied by age, with patients under 50 showing different utilization of chemotherapy, immunotherapy, and metastasis resection compared to

CRC Research Finding

Skip to content The CRC Digest ▪ CRC incidence after polypectomy tracked in UK Biobank cohort UK Biobank data showed that during median 10-year follow-up after polypectomy, 78 incident colorectal cancers occurred (153 per 100,000 person-years). The study compared risk between the removal group and both the non-index-colonoscopy group and